antiretroviral therapy outcomes in hiv-infected children after adjusting protease inhibitor dosing during tuberculosis treatment抗逆转录病毒治疗结果的艾滋病毒感染儿童调整后蛋白酶抑制剂在结核病治疗剂量.pdfVIP

Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment 1 2 2 3 2 1 Cordula Frohoff , Magendhree Moodley , Lee Fairlie , Ashraf Coovadia , Harry Moultrie , Louise Kuhn , Tammy Meyers4* 1 Gertrude H. Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America, 2 Wits Institute for Sexual Reproductive Health HIV Related Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 3 Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4 Harriet Shezi Clinic, Chris Hani Baragwanath Hospital, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Abstract Background: Modification of ritonavir-boosted lopinavir (LPV/r)-based antiretroviral therapy is required for HIV-infected children co-treated for tuberculosis (TB). We aimed to determine virologic and toxicity outcomes among TB/HIV co-treated children with the following modifications to their antiretroviral therapy (ART): (1) super-boosted LPV/r, (2) double-dose LPV/r or (3) ritonavir. Methods and Findings: A medical record review was conducted at two clinical sites in Johannesburg, South Africa. The records of children 6–24 months of age initiating LPV/r-based therapy were reviewed. Children co-treated for TB were categorized based on the modifications made to their ART regimen and were compared to children of the same age at eac